Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 54.97%
March 31, 2026 51.78%
December 31, 2025 50.26%
September 30, 2025 49.07%
June 30, 2025 53.69%
March 31, 2025 51.34%
December 31, 2024 46.02%
September 30, 2024 46.86%
June 30, 2024 47.56%
March 31, 2024 53.55%
December 31, 2023 47.88%
September 30, 2023 51.98%
June 30, 2023 51.12%
March 31, 2023 50.92%
December 31, 2022 46.08%
September 30, 2022 43.86%
June 30, 2022 33.58%
March 31, 2022 24.27%
December 31, 2021 21.91%
September 30, 2021 31.31%
June 30, 2021 30.82%
March 31, 2021 43.36%
December 31, 2020 38.10%
September 30, 2020 40.59%
June 30, 2020 34.20%
Date Value
March 31, 2020 33.73%
December 31, 2019 52.55%
September 30, 2019 52.32%
June 30, 2019 53.82%
March 31, 2019 41.71%
December 31, 2018 49.55%
September 30, 2018 52.36%
June 30, 2018 47.31%
March 31, 2018 37.85%
December 31, 2017 41.91%
September 30, 2017 41.50%
June 30, 2017 36.95%
March 31, 2017 36.96%
December 31, 2016 40.54%
September 30, 2016 41.25%
June 30, 2016 43.35%
March 31, 2016 60.99%
December 31, 2015 68.67%
September 30, 2015 73.43%
June 30, 2015 76.66%
March 31, 2015 78.31%
December 31, 2014 76.45%
September 30, 2014 75.57%
June 30, 2014 57.53%
March 31, 2014 69.49%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Ocular Therapeutix, Inc. 85.08%
Liquidia Corp. 93.10%
Elanco Animal Health, Inc. 48.17%
Harmony Biosciences Holdings, Inc. 73.53%
Corcept Therapeutics, Inc. 98.41%